By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
High-definition radiotherapy, also known as HDRT, is a cutting-edge technique in radiation oncology that has revolutionized cancer treatment.
It is a form of external beam radiation therapy that delivers highly precise and targeted doses of radiation to cancerous tumors while minimizing damage to surrounding healthy tissues.
This advanced technology employs state-of-the-art imaging and planning systems to create detailed three-dimensional maps of the tumor, allowing radiation oncologists to precisely shape the radiation beams.
The key advantage of high-definition radiotherapy lies in its ability to deliver higher radiation doses to tumors, leading to improved tumor control rates.
By precisely targeting the cancerous cells, HDRT maximizes the radiation dose to the tumor while minimizing exposure to healthy tissues, reducing the risk of side effects.
This is achieved through the use of advanced imaging techniques such as computed tomography (CT) scans and magnetic resonance imaging (MRI) to precisely localize the tumor and track its movement during treatment.
One of the significant advancements in HDRT is the incorporation of image-guided radiation therapy (IGRT). IGRT enables real-time imaging of the tumor immediately before or during treatment, ensuring accurate targeting even if there are variations in tumor position or shape.
This level of precision allows for adaptive treatment planning, where the radiation dose can be modified during the course of treatment based on changes observed in the tumor.
Additionally, HDRT techniques often utilize intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT), which allow for highly conformal dose distributions.
These techniques shape the radiation beams to match the exact contours of the tumor, maximizing dose delivery to the cancer cells while minimizing exposure to surrounding healthy tissues.
The Global High-definition radiotherapy market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
TrueBeam™ is a cutting-edge radiation therapy system developed by Varian Medical Systems. It combines advanced imaging and precision delivery techniques to treat cancer patients with utmost accuracy and efficiency.
TrueBeam™ offers a versatile treatment platform capable of delivering various radiation therapy techniques, including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic body radiation therapy (SBRT).
It integrates advanced imaging technologies like on-board imaging and cone-beam CT to ensure precise tumor targeting and minimize radiation exposure to healthy tissues.
With its sophisticated software, customizable treatment options, and fast delivery times, TrueBeam™ provides clinicians with a powerful tool to improve cancer treatment outcomes and enhance patient comfort.
Accuray Radixact® is an advanced radiation therapy system developed by Accuray Incorporated, a global medical device company.
The Radixact® offers precise and highly targeted radiation treatment for various types of cancer, providing personalized therapy options to improve patient outcomes.
Its integrated imaging system enables real-time imaging during treatment, allowing for adjustments based on changes in patient anatomy or tumor position.
The Radixact utilizes the Synchrony® technology, which tracks and adapts to patient respiratory motion, minimizing radiation exposure to surrounding healthy tissues.
This state-of-the-art system aims to deliver safe and effective radiation therapy, ultimately leading to improved patient quality of life.
